Aethlon Medical, Inc. (Nasdaq: AEMD) reported the results of its Annual Meeting of Stockholders, held virtually on October 1, 2026. At the meeting, stockholders approved several proposals, including amendments to the company's equity incentive plan and its articles of incorporation.
The primary proposal approved by stockholders was an amendment to the company's 2020 Equity Incentive Plan. This amendment, which became effective on October 1, 2026, increases the number of shares of common stock authorized for issuance under the plan by 100,000 shares. The amendment had previously been approved by the Board of Directors on July 10, 2026, subject to stockholder approval.
Stockholders also approved an amendment to the company's Articles of Incorporation to increase the number of authorized shares of common stock from 20,000,000 to 200,000,000. Additionally, stockholders approved an amendment to the Articles of Incorporation to authorize 20,000,000 shares of preferred stock, par value $0.001 per share, and authorize the Board of Directors to establish one or more series thereof.
Other proposals approved at the meeting included the ratification of Haskell & White LLP as the company's independent registered public accounting firm for the fiscal year ending March 31, 2027, and an advisory vote on the compensation of named executive officers.
At the close of business on August 10, 2026, the record date for the Annual Meeting, there were 711,136 shares of Company common stock issued and outstanding. At the meeting, 399,752 shares, or approximately 56.21%, were represented by proxy or in person.
